You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
復星醫藥(600196.SH):復宏漢霖簽署許可協議
格隆匯 01-14 17:52

格隆匯1月14日丨復星醫藥(600196.SH)公佈,公司控股子公司上海復宏漢霖生物技術股份有限公司(以下簡稱“復宏漢霖”)獲Chiome Bioscience, Inc.(以下簡稱“Chiome”)獨佔許可在區域內(即中國大陸及港澳台,以及因行使被許可方選擇權而擴展的全球其他地域,下同)及領域內(即所有人體治療及診斷應用,下同)就針對人體TROP2靶點的抗體產品(以下簡稱“許可產品”)開展研發、生產及商業化(包括但不限於研究、開發、生產、製造、使用、銷售、要約銷售、上市、商業化、分銷和進口等行為)並使用相關知識產權。

許可產品是針對人體TROP2靶點的創新單克隆抗體,截至本公吿日尚處於臨牀前研究階段。根據已進行的臨牀前研究,許可產品具有開發抗體偶聯藥物、雙特異性抗體、與多種抗體聯合治療的潛力。TROP2(即滋養層細胞表面抗原2)是一種單次跨膜糖蛋白,在多種實體腫瘤表面高表達,其靶向藥物的潛在適應症包括三陰乳腺癌、非小細胞肺癌及尿路上皮癌等。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account